Provided by Tiger Fintech (Singapore) Pte. Ltd.

Halozyme Therapeutics

54.00
+0.16000.30%
Post-market: 54.050.0500+0.09%16:20 EDT
Volume:867.67K
Turnover:46.81M
Market Cap:6.65B
PE:14.37
High:54.17
Open:53.54
Low:53.33
Close:53.84
Loading ...

Halozyme Therapeutics Joins Russell 1000 Index

MT Newswires Live
·
01 Jul

Halozyme Therapeutics Inc. Joins Russell 1000® Index

Reuters
·
01 Jul

Helen Torley, President and CEO, Reports Disposal of Common Shares in Halozyme Therapeutics Inc

Reuters
·
25 Jun

European Commission Approves VYVGART® Subcutaneous Injection with ENHANZE® for CIDP, Expanding Argenx and Halozyme's Reach in Europe

Reuters
·
21 Jun

Merck granted review of Halozyme patent claims by PTAB

TIPRANKS
·
03 Jun

Halozyme Therapeutics Price Target Maintained With a $72.00/Share by HC Wainwright & Co.

Dow Jones
·
29 May

Halozyme Therapeutics Inc. to Participate in Goldman Sachs 46th Annual Global Healthcare Conference 2025

Reuters
·
29 May

Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (Nivolumab) Co-Formulated With Enhanze® Across Multiple Solid Tumor Indications

THOMSON REUTERS
·
28 May

Analysts Offer Insights on Healthcare Companies: Halozyme (HALO), Genmab (GMAB) and Vir Biotechnology (VIR)

TIPRANKS
·
22 May

Halozyme Therapeutics Shares Fall After Morgan Stanley Downgrade

MT Newswires Live
·
15 May

BUZZ-Halozyme falls after Morgan Stanley downgrades

Reuters
·
15 May

Halozyme Therapeutics Cut to Equal-Weight From Overweight by Morgan Stanley

Dow Jones
·
14 May

Halozyme Therapeutics, Inc : Morgan Stanley Cuts to Equal-Weight From Overweight

THOMSON REUTERS
·
14 May

Halozyme Shares Fall After Leerink Partners Downgrade

MT Newswires Live
·
14 May

Halozyme Slides On Potential Revenue Pressure Concerns -- Market Talk

Dow Jones
·
14 May

Big Pharma Counted On a Price Negotiation Loophole. It May Be Closing. -- Barrons.com

Dow Jones
·
14 May

Halozyme Therapeutics Cut to Underperform From Market Perform by Leerink Partners

Dow Jones
·
13 May

Stock Track | Halozyme Therapeutics Plummets 20% After Leerink Partners Downgrades to Underperform

Stock Track
·
13 May

Leerink Partners Downgrades Halozyme Therapeutics to Underperform From Market Perform, Price Target is $47

MT Newswires Live
·
13 May

Halozyme Therapeutics, Inc : Morgan Stanley Raises Target Price to $73.00 From $67.00

THOMSON REUTERS
·
08 May